Amneal Lifts 2026 Revenue Outlook to $3.10B-$3.20B
AMRX has more than doubled off its 52-week low of $7.665.
Summary
Amneal raised its full-year 2026 revenue guidance to $3.10B-$3.20B, up from $3.05B-$3.15B, and also increased its adjusted EPS outlook to $0.96-$1.06 from $0.95-$1.05. The stock is already trading near a 52-week high, reflecting recent positive catalysts including FDA approvals and a pending Kashiv BioSciences acquisition. This upward revision adds to the momentum, suggesting the pipeline and commercial execution are delivering ahead of plan. The Kashiv deal, set for a shareholder vote, could further reshape the growth trajectory.
Updates
· SEC 8-K — Q2 net revenue was $796 million, up 10% year over year; adjusted EBITDA was $206 million and adjusted diluted EPS was $0.30. Amneal repriced its $2.084B Term Loan B to SOFR plus 250 basis points, expected to save about $12 million in annual cash interest.
At the time of this announcement, AMRX was trading at $20.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $7.67 to $19.26. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.